2m 2m 2m 2m 2m 2m 2m
CytomX Therapeut (CTMX)
NASDAQ
$3.18+$0.14 (+4.57%)
Price as of Jun 23, 2026 7:55 PM EDT- $661.8MMarket Cap
- 40.74%1-Year Change
- BiotechnologyIndustry
CytomX Therapeut (CTMX)
$3.18+$0.14 (+4.57%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 76.2M -44.82% | 138.1M +36.45% | 101.2M +90.38% | 53.2M +42.48% | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 76.2M -44.82% | 138.1M +36.45% | 101.2M +90.38% | 53.2M +42.48% | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -68.7M -17.57% | -83.4M +7.34% | -77.7M -30.42% | -111.6M -2.23% | |
Depreciation and Amortization Expense | 146,000 0.00% | 146,000 0.00% | 146,000 0.00% | 146,000 0.00% | |
Total Operating Expenses | 98.6M -12.86% | 113.1M +5.02% | 107.7M -30.29% | 154.5M +0.75% | |
Operating Profit | -22.4M -189.47% | 25.0M +485.49% | -6.5M -93.60% | -101.3M -12.67% | |
Interest Income | 5.2M -27.05% | 7.1M -27.46% | 9.8M +486.23% | 1.7M +558.04% | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 5.2M -27.05% | 7.1M -27.46% | 9.8M +486.23% | 1.7M +558.04% | |
Total Nonoperating Income and Expense | 28,000 +173.68% | -38,000 +26.67% | -30,000 -108.82% | 340,000 +509.64% | |
Income before Taxes | -17.1M -153.38% | 32.1M +865.78% | 3.3M +103.35% | -99.3M -14.29% | |
Income Taxes | 238,000 +6.25% | 224,000 -94.24% | 3.9M N/A | 0 N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -17.4M -154.50% | 31.9M +5,700.88% | -569,000 -99.43% | -99.3M -14.29% | |
Net Income from Continuing Operations Applicable to Common | -20.4M -163.47% | 32.1M +865.78% | 3.3M +103.35% | -99.3M -14.29% | |
Basic EPS and Net Income | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Diluted EPS and Net Income | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Basic Weighted Average Shares | 137.9M +63.36% | 84.4M +14.40% | 73.8M +12.27% | 65.7M +2.48% | |
Diluted Weighted Average Shares | 137.9M +62.77% | 84.7M +14.82% | 73.8M +12.27% | 65.7M +2.48% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 12.7M -66.71% | 38.1M +121.61% | 17.2M -91.13% | 193.7M -5.78% | |
Short-Term Investments | 124.4M +98.79% | 62.6M -60.23% | 157.3M N/A | 0 -100.00% | |
Cash and Cash Equivalents and Short-Term Investments | 137.1M +36.20% | 100.6M -42.34% | 174.5M -9.88% | 193.7M -36.56% | |
Total Current Assets | 143.9M +34.12% | 107.3M -41.34% | 182.9M -22.85% | 237.1M -23.59% | |
Accumulated Depreciation | 16.9M +4.24% | 16.2M +10.51% | 14.7M +2.19% | 14.4M +3.91% | |
Property and Plant and Equipment and Net | 1.3M -47.14% | 2.5M -37.67% | 4.0M -21.96% | 5.1M -14.90% | |
Total Long-Term Assets | 31,000 -53.03% | 66,000 -20.48% | 83,000 +207.41% | 27,000 -97.00% | |
Total Assets | 151.6M +25.75% | 120.5M -40.27% | 201.8M -22.65% | 260.9M -23.13% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 46.6M -45.65% | 85.8M -44.99% | 155.9M +2.17% | 152.6M +95.98% | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 4.4M +5.78% | 4.1M +5.70% | 3.9M -97.99% | 194.0M -25.94% | |
Total Liabilities | 52.6M -56.56% | 121.0M -51.46% | 249.2M -28.10% | 346.6M +1.99% | |
Retained Earnings | -711.9M +2.95% | -691.6M -4.41% | -723.4M +0.08% | -722.9M +15.93% | |
Total Stockholders Equity | 99.0M +21,812.28% | -456,000 -99.04% | -47.4M -44.67% | -85.8M +18,582.14% | |
Total Shares Outstanding | 170.2M +112.47% | 80.1M +19.00% | 67.3M +1.63% | 66.2M +1.28% | |
Cash Flow | |||||
Cash from Operating Activities | -75.6M -12.34% | -86.2M +53.89% | -56.0M -49.42% | -110.8M -6.93% | |
Capital Expenditures | 220,000 -29.03% | 310,000 -63.10% | 840,000 -51.72% | 1.7M +8.14% | |
Cash from Investing Activities | -59.7M -159.92% | 99.7M +166.17% | -150.7M -253.34% | 98.3M +336.92% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 110.4M +1,368.31% | 7.5M -75.12% | 30.2M +4,565.12% | 648,000 -99.41% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | -29.35% -262.16% | 18.10% +382.52% | -6.41% -96.64% | -190.61% -38.71% | |
Return on Assets | -12.77% -164.56% | 19.77% +8,138.41% | -0.25% -99.26% | -33.09% -0.33% | |
Return on Equity | -35.25% -73.51% | -133.06% -15,673.08% | 0.85% -99.63% | 230.41% +149.06% | |
Revenue Growth | -44.82% -222.98% | 36.45% -59.68% | 90.38% +112.76% | 42.48% +167.62% | |
Current Ratio | 3.09 +146.79% | 1.25 +6.62% | 1.17 -24.48% | 1.55 -61.01% | |
Cash Ratio | 0.27 -38.75% | 0.44 +302.91% | 0.11 -91.32% | 1.27 -51.92% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow